These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 31713086)

  • 1. Real-world comparisons of reduced-dose non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation: a systematic review and meta-analysis.
    Wang X; Fang L; Liu B; Zheng Y; Zeng J
    Heart Fail Rev; 2020 Nov; 25(6):973-983. PubMed ID: 31713086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease: A Meta-Analysis and Systematic Review.
    Fu Y; Zhu W; Zhou Y; Chen H; Yan L; He W
    Am J Cardiovasc Drugs; 2020 Apr; 20(2):139-147. PubMed ID: 31485852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Asians With Atrial Fibrillation: Meta-Analysis of Randomized Trials and Real-World Studies.
    Xue Z; Zhang H
    Stroke; 2019 Oct; 50(10):2819-2828. PubMed ID: 31422735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Deng Y; Tong Y; Deng Y; Zou L; Li S; Chen H
    J Am Heart Assoc; 2019 Jul; 8(14):e012540. PubMed ID: 31310583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.
    Wang KL; Lopes RD; Patel MR; Büller HR; Tan DS; Chiang CE; Giugliano RP
    Eur Heart J; 2019 May; 40(19):1492-1500. PubMed ID: 30590440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of non-vitamin K antagonist oral anticoagulants versus warfarin in heart failure patients with atrial fibrillation.
    Chen F; Zhou Y; Wan Q; Yu P; Ma J; Hu J
    Heart Fail Rev; 2021 Nov; 26(6):1391-1397. PubMed ID: 32249407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: evidences from the real-world data.
    Xue Z; Zhou Y; Wu C; Lin J; Liu X; Zhu W
    Heart Fail Rev; 2020 Nov; 25(6):957-964. PubMed ID: 31655947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Appropriate doses of non-vitamin K antagonist oral anticoagulants in high-risk subgroups with atrial fibrillation: Systematic review and meta-analysis.
    Kim IS; Kim HJ; Kim TH; Uhm JS; Joung B; Lee MH; Pak HN
    J Cardiol; 2018 Oct; 72(4):284-291. PubMed ID: 29706404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation with Coronary or Peripheral Artery Disease.
    Zhang H; Xue Z; Yi D; Li X; Tan Y; Li J
    Int Heart J; 2020 Mar; 61(2):231-238. PubMed ID: 32173695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of the efficacy and safety of non-vitamin K antagonist oral anticoagulants with warfarin in Latin American patients with atrial fibrillation.
    Su Z; Zhang H; He W; Ma J; Zeng J; Jiang X
    Medicine (Baltimore); 2020 May; 99(18):e19542. PubMed ID: 32358343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.
    Ruff CT; Giugliano RP; Braunwald E; Hoffman EB; Deenadayalu N; Ezekowitz MD; Camm AJ; Weitz JI; Lewis BS; Parkhomenko A; Yamashita T; Antman EM
    Lancet; 2014 Mar; 383(9921):955-62. PubMed ID: 24315724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation Using P-gp and/or CYP450-Interacting Drugs: a Systematic Review and Meta-analysis.
    Grymonprez M; Vanspranghe K; Steurbaut S; De Backer TL; Lahousse L
    Cardiovasc Drugs Ther; 2023 Aug; 37(4):781-791. PubMed ID: 34637052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Peripheral Artery Disease: a Systematic Review and Meta-Analysis.
    Liao XZ; Fu YH; Ma JY; Zhu WG; Yuan P
    Cardiovasc Drugs Ther; 2020 Jun; 34(3):391-399. PubMed ID: 32206988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation: a systematic review and meta-analysis.
    Zhou Y; He W; Zhou Y; Zhu W
    J Thromb Thrombolysis; 2020 Aug; 50(2):311-317. PubMed ID: 31792707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
    Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
    Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP;
    Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin.
    Dogliotti A; Paolasso E; Giugliano RP
    Clin Cardiol; 2013 Feb; 36(2):61-7. PubMed ID: 23338902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis.
    Savarese G; Giugliano RP; Rosano GM; McMurray J; Magnani G; Filippatos G; Dellegrottaglie S; Lund LH; Trimarco B; Perrone-Filardi P
    JACC Heart Fail; 2016 Nov; 4(11):870-880. PubMed ID: 27614940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.